ÔËÐм¼ÊõÔ± 4500-5999 ÊÕ²Ø ÉêÇëְλ
Ê×Ò³ > Ì©ÖÝÕÐƸ > ÔËÐм¼ÊõÔ±

ÔËÐм¼ÊõÔ±

Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾

Ë¢ÐÂÓÚ£º2023-12-12±»ä¯ÀÀ£º597´Î

4500-5999

²»ÏÞ / ÖÐר / ÐÔ±ð²»ÏÞ / 1 / ²»ÏÞµ½¸Ú

½­ËÕ-Ì©ÖÝ £¨Ì©ÖÝÒ½Ò©¸ßм¼Êõ²úÒµÔ°¿Ú̩·Î÷²à½¼Ò·¶«²àG79´± £© ÉÏ°à·Ïß²éѯ

ÕÐƸ1

³Â
ְλ·¢²¼ÈË£º³ÂÏÈÉú

139****6549,052****713092 ÏÔʾºÅÂë

(ÁªÏµÊ±Çë˵Ã÷ÊÇÔÚÐÂÌ©ÖÝÈ˲ÅÍøÉÏ¿´µ½µÄ)

´òµç»°Ç°ÏÈͶ¸ö¼òÀú£¬»ñµÃÃæÊԵijɹ¦ÂÊÔö¼Ó30%

Ì©ÖÝÈ˲ÅÍøÌáʾ£ºÌ©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾ÎÞȨÊÕÈ¡ÈκηÑÓã¬Çë¹ã´óÇóÖ°Õß¼ÓÇ¿×ÔÎÒ±£»¤Òâʶ£¬°´ÀͶ¯·¨¹æ±£»¤×ÔÉíȨÒ棬¾¯ÌèÐé¼ÙÕÐƸ,±ÜÃâÉϵ±ÊÜÆ­£¡ ¾Ù±¨´Ëְλ
ְλÃèÊö

¸ÚλְÔð£º1¸ºÔð¿Õµ÷ϵͳˮϵͳ¶¯Á¦ÖÐÐÄÎÛË®ÉèÊ©µÄѲ²éºÍ²Ù×÷£¬Ð­×÷±£Ñø£»

2°´ÒªÇó¼°Ê±×öºÃ¼Ç¼£¬×öÕæ×öʵ£»

3¼°Ê±Á˽âʹÓò¿ÃÅÎÂʪ¶È»·¾³£¬²¢¼°Ê±Î¬»¤£¬È·±£»

·¾³·ûºÏÒªÇó£»

4×öºÃ½»½Ó°à£¬ÓëÒì³£Çé¿ö¼°Ê±»ã±¨£»

5Íê³ÉÆäËû±¾Ö°¹¤×÷¡£
ÈÎÖ°ÒªÇó£º1ÈýÄê¼°ÒÔÉϹ¤×÷¾­Ñ飬ÖÆÒ©ÐÐÒµÓÅÏÈ£»

2ÄÜÊÊÓ¦Á½°àµ¹£¬ÉÏÒ¹°à£»

3»úµçµç×Ó»¯¹¤µÈÏà¹Øרҵ£»

4Óе繤֤ÕßÓÅÏÈ¿¼ÂÇ¡£
5Ó¦½ìÉúÒ²¿É¡£

¹«Ë¾¼ò½é
Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾ÓÚ2015ÄêÈëפ̩ÖÝÊÐÖйúÒ½Ò©³Ç£¬×¢²á×ʱ¾2000ÍòÃÀÔª¡£¹«Ë¾Ö÷Òª´Óʵ¥¿¹Ò©ÎïÉú²ú£¬Í¶×Ê×ܶî2ÒÚÃÀÔª£¬Ä⽨³§·¿Ãæ»ý3ÍòÓàƽ·½£¬½¨Éè·ûºÏGMP±ê×¼µÄ¹ú¼ÊÏȽøµÄ¿¹ÌåÒ©ÎïÖƱ¸Ìåϵ£¬ÒÔÆÚ´òÔì¹úÄÚ¿¹ÌåÒ©ÎïÉú²ú¸ßµØ¡£Âõ²©Ì«¿ÆÒ©ÒµÓÉÉϺ£ÕŽ­ÉúÎï¼¼ÊõÓÐÏÞ¹«Ë¾£¨¿¹ÌåÒ©ÎïÓë°ÐÏòÖÎÁƹú¼ÒÖصãʵÑéÊÒ£©¿¹ÌåÑз¢ÍŶÓÌṩһվʽƽ̨·þÎñ£¬ÖÂÁ¦ÓÚʵÏÖһϵÁÐÖØÁ¿¼¶¹ú¼Ò´´Ð¿¹ÌåÒ©ÎïµÄ²úÒµ»¯¡£ÏÖÓÐÆ·ÖÖ£ºÖÎÁƽáÖ±³¦°©µÄÖØ×鿹EGFRÈËÊóǶºÏµ¥¿Ë¡¿¹Ì壬ÖÎÁÆÒøм²¡µÄÖØ×éÈËLFA3-¿¹ÌåÈںϵ°°×µÈ¡£TaizhouMabtechPharmaceuticalCo.,Ltd.joinedtheChinaMedicalCity(CMC)in2015withregisteredcapitalofUSD20million,expandinganationalhighlandformonoclonalantibodymedicinemanufacturingbyestablishinginternationallyadvancedantibodymedicinemanufacturesystemwithadoptedcGMPstandards,withatotalinvestmentofUSD200million.Supportedbytheone-stopplatformfortherapeuticmAbmedicinedevelopmentprovidedbyZJ-BioR&DTeam(StateKeyLaboratoryofAntibodyMedicineandTargetedTherapy),TaizhouMabtechPharmaceuticsCo.,Ltdisdedicatedtoindustrializationofaseriesof¡°blockbuster¡±innovativeantibodydrugs.Existingvarieties:recombinantanti-EGFRhuman/mouse-chimericmonoclonalantibodyforthetreatmentofcolorectalcancer,recombinanthumanLFA3-antibodyfusionproteinforthetreatmentofpsoriasis,etal.
¸Ã¹«Ë¾µÄÆäTAְλ
Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾
  • ÖÆÔìÒµ
  • ÍâÉÌͶ×ÊÆóÒµ
  • ½­ËÕ-Ì©ÖÝ
  • 100-1000ÈË
0%¼òÀú·´À¡ÂÊ
0ƽ¾ù»Ø¸´Ê±³¤
1¸öÕÐƸְλ
ְλÃû³Æ£ºÔËÐм¼ÊõÔ±
¹«Ë¾Ãû³Æ£º Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾
 
ÏàËÆְλ